Estelle Mei Jye Foo

Estelle Mei Jye Foo

Auto-generated profile, based on publicly available information

Estelle Mei Jye Foo

Division of Medical Oncology, National Cancer Centre Singapore, Singapore

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in JCO Global Oncology
Verified
Journal Article
Open access
Eva SegelovEva Segelov
Eva Segelov
HPHans Prenen
Hans Prenen
DDDaphne Day
Daphne Day
RMRaina MacIntyre
Raina MacIntyre
EFEstelle Mei Jye Foo
Estelle Mei Jye Foo
OIon behalf of the ASCOLT Investigators
on behalf of the ASCOLT Investigators

1 September 2023 in JCO Global Oncology
Verified
Journal Article
Open access
DDDaphne Day
Daphne Day
HTHan Chong Toh
Han Chong Toh
RARaghib Ali
Raghib Ali
EFEstelle Mei Jye Foo
Estelle Mei Jye Foo
JSJohn Simes
John Simes
OIon behalf of the ASCOLT Investigators
on behalf of the ASCOLT Investigators
PURPOSE: The Asia-Pacific (APAC) region is a major focus for multinational clinical trials, although its cultural, linguistic, economic, and regulatory diversity pose significant challenges for trial conduct, particularly for academic clinical trials. METHODS: We describe our experience running the investigator-initiated phase III randomized, fully accrued, Aspirin for Dukes C and high-risk Dukes B Colorectal cancer trial (ASCOLT, ClinicalTrials.gov identifier: NCT00565708 , N = 1,587), studying the benefit of aspirin in resected high-risk colorectal cancer. ASCOLT opened in 2008 and is the first large academic adjuvant trial fully conducted in the APAC region. Centrally coordinated by the Trial Management Team at the National Cancer Centre Singapore, it has involved 74 sites across 12 APAC countries/regions, including five middle-income countries. RESULTS: Challenges encountered included regulatory complexity, communication and logistical barriers, limited funding and resources, disparate experience and infrastructure across sites, recruitment holds because of changes in local laws, patient attrition, and disruptions caused by the COVID-19 pandemic. Over 100 contracts and 49 ethics board reviews were required, contributing to a lengthy prestudy preparation time of 2 years and start-up times of approximately 6 months per site. Some of the mitigating actions included engaging local cooperative groups (eg, the Australasian Gastro-Intestinal Trials Group in Australia and New Zealand) and seven contract research organizations to manage sites, regular communication with the central team, transition to electronic data management, and a centralized drug-dispensing system. CONCLUSION: To ensure an efficient and patient-centered clinical trials environment in the APAC region and sustained growth, we suggest coordinated approaches to harmonize regulatory processes, APAC academic oncology trials consortia to streamline processes and provide governance, and ongoing commitment from governments, funding agents, and industry.

20 July 2026 in EBioMedicine
Verified
Journal Article
Open access
Eva SegelovEva Segelov
Eva Segelov
SLShan Li
Shan Li
ILIsabel Li
Isabel Li
DMDmitri Mouradov
Dmitri Mouradov
SYSonia Yip
Sonia Yip
RSRobert John Simes
Robert John Simes